Mirabegron might cause headache, urinary retention, and hypertension in certain patients. This clinical trial has excluded patients with severe cardiovascular diseases from the study. If the patients have side effects from the drug used in this study, the researcher will stop giving medication to the patient, and treat the complications accordingly. headache, urinary retention, and hypertension in certain patients.
Conditions
Interventions
Placebo 1 tab po OD pc,Mirabegron(50) 1 tab po OD pc
Placebo Comparator Drug,Active Comparator Drug
Sponsors
Faculty of medicine Ramathibodi Hospital Mahidol University
Eligibility
Sex/Gender
All
Age
19 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Duration of age is 19-80 years 2. The patients undergoing DJ stent insertion after ureteroscopy, retrograde intrarenal surgery 3. The patients undergoing DJ stent insertion from other causes of urinary obstruction including pelvic and intraabdominal malignancies. 4. The patients have to be literate. 5. The patients are willing to be in the study. 4.Research participants must be able to read and write.
Exclusion criteria
Exclusion criteria: 1. Patients using the alpha blockers, anticholinergics more than 2 weeks. 2. Patients using the Mirabegron continuously for more than 1 week. 3. Patients with previous exploratory laparotomy or other open abdominal surgery. 4. Patients with stents on both sides. 5. Pregnant and lactating patients. 6. Patients with Severe cardiovascular or cerebrovascular disease. 7. Patient has uncontrolled hypertension. 8. Patients allergic to Mirabegron 9. The patient refused and asked to withdraw.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary stent symptoms scores 1 month Urinary symptoms score questionnaire | — |
Secondary
| Measure | Time frame |
|---|---|
| side effects 1 month numbers of adverse events | — |
Countries
Thailand
Contacts
Public ContactMookdarat Siantong
Faculty of medicine Ramathibodi Hospital Mahidol University
Outcome results
None listed